REXAHN PHARMACEUTICALS ON FEB 8, ENTERED INTO EXCLUSIVE LICENSE AGREEMENT WITH ZHEJIANG HAICHANG BIOTECHNOLOGY
* HAICHANG WILL PAY CO DEVELOPMENT MILESTONE PAYMENTS OF UP TO $63
MILLION WITH RESPECT TO RX-0201 & RX-0301, UP TO $33 MILLION WITH
RESPECT TO RX-0047
* REXAHN GRANTED HAICHANG EXCLUSIVE SUBLICENSABLE WORLDWIDE LICENSE
TO RESEARCH, DEVELOP, COMMERCIALIZE PRODUCTS COMPRISING RX-0201,RX-0301,
RX-0047 Source text: (bit.ly/2vo1A88)
https://www.reuters.com/article/brief-rexahn-pharmaceuticals-says-on-feb/brief-rexahn-pharmaceuticals-says-on-feb-8-co-entered-into-exclusive-license-agreement-with-zhejiang-haichang-biotechnology-idUSFWN2AA18E
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.